In vivo integrity of polymer-coated gold nanoparticles by Kreyling, Wolfgang G. et al.
In vivo integrity of polymer-coated gold nanoparticles 
 
Wolfgang G. Kreyling1*, Abuelmagd M. Abdelmonem2+, Zulqurnain Ali2,3+, Alexander Wenk1+, 
Frauke Alves4,5+, Marianne Geiser6+, Stephanie Hirn1,7+, Raimo Hartmann2+, Karsten Kantner2+, 
Nadine Haberl1,7+, Dorleta Jimenez de Aberasturi2,8,9+, Gülnaz Khadem-Saba1,10+, Jose-Maria 
Montenegro2,11+, Joana Rejman2+, Teofilo Rojo8+, Idoia Ruiz de Larramendi8+, Roser Ufartes4+, 
Wolfgang J. Parak2,9* 
 
1 Institute of Lung Biology and Disease and Institute of Epidemiology 2, Helmholtz Zentrum 
München – German Research for Center for Environmental Health, 85764 Neuherberg / 
Munich, Germany  
2 Fachbereich Physik, Philipps Universität Marburg, Marburg, Germany 
3 present address: Department of Physics, Air University, Sector E-9, 44000 Islamabad, 
Pakistan 
4 Department of Molecular Biology of Neuronal Signals, Max-Planck-Institut für 
Experimentelle Medizin, 37075 Göttingen, Germany 
5 Department of Hematology and Oncology, University Medical Center Göttingen, Göttingen 
37075, Germany 
6 Institute of Anatomy, University of Bern, 3012 Bern, Switzerland 
7 present address: Walter Brendel Centre of Experimental Medicine, Ludwig-Maximilians-
University, 81377 Munich, Germany 
8 Department of Inorganic Chemistry, UPV/EHU, Bilbao, Spain 
9 CIC Biomagune, San Sebastian, Spain 
10 present address: Department of Chemistry, Industrial Biocatalysis, Technische Universität 
München (TUM), 85748 Garching, Germany 
11 present address: Central Research Services, University of Malaga, 29071 Málaga, Spain. 
+ authors listed in alphabetic order 
* corresponding authors: kreyling@helmholtz-muenchen.de, wolfgang.parak@physik.uni-
marburg.de 
 
Keywords 
colloidal nanoparticles, double radioactive labelling of NPs, in vivo biodistribution, intravenous 
injection, enzymatic degradation 
 
  
Inorganic nanoparticles (NPs) are frequently engineered with an organic surface coating to 
improve their physicochemical properties, and it is well-known that their colloidal properties1 
may change upon internalization by cells2, 3. While the stability of such NPs is typically assayed 
in simple in vitro tests, their stability in a mammalian organism remains unknown. Here, we 
show that firmly grafted polymer shells around gold NPs may degrade when injected into rats. 
We synthesized monodisperse radioactively labelled gold nanoparticles (198Au)4 and engineered 
an 111In-labelled polymer shell around them5. Upon intravenous injection into rats, quantitative 
biodistribution analyses performed independently for 198Au and 111In showed partial removal of 
the polymer shell in vivo. While 198Au accumulates mostly in the liver, part of the 111In shows a 
non-particulate biodistribution similar to intravenous injection of chelated 111In. Further in vitro 
studies suggest that degradation of the polymer shell is caused by proteolytic enzymes in the 
liver. Our results show that even NPs with high colloidal stability can change their physico-
chemical properties in vivo.  
 
Upon internalization by cells, NPs are typically localized inside highly acidic endosomes and/or 
lysosomes. NPs are often stabilized by negatively charged groups (such as -COO-) having pKa 
values higher than the low pH values in the endosomes and lysosomes6. Thus, internalization 
leads to loss of charge and in consequence agglomeration7. Reduced pH also can enhance 
corrosion of NPs8, resulting in release of toxic ions, as in the case of CdSe9, 10 or Ag NPs11, 12. 
Besides changing the NP core properties, uptake by cells can also lead to a removal of their 
surface capping both in vitro, as shown for polymer-coated3, 13 and dextrane-coated NPs14, and in 
vivo15, 16. Intracellular enzymes may degrade the corona of adsorbed proteins2, or may modify the 
surface chemistry of the NPs17, 18. To trace the fate of the different components of a NP – that is, 
the inorganic core, the organic surface capping, and the protein corona – each of these 
components needs to be labelled individually. Here, we labelled the core and shell of 
monodisperse Au NPs with radioisotopes5 (Figure 1), and followed their respective 
biodistribution in vivo. Equal biokinetics of both radiolabels would indicate in vivo stability of the 
NPs, whereas different biodistributions would indicate partial degradation.  
 
  
Au NPs with 198Au label in their core and 111In in their shell were intravenously injected into rats, 
which were sacrificed after 1 h or 24. Then complete organs of the rats were sampled and 198Au 
and 111In radioactivities originating from the different organs were measured4, 19. Blood contents 
of organs and the remaining body were calculated according to the findings of Oeff et al.20. In 
Figure 2a-d and Supplementary Fig. 25 the quantitatively balanced biodistributions (i.e. the sum 
of all 198Au radioactivities and of all 111In radioactivities as detected in all organs and tissues, the 
remaining carcass, and total faecal and urinary excretion is 100 %) are shown. For a detailed 
analysis of these data the stability of the radioactive labels needs to be known. The 198Au within 
the stable 197Au matrix resulting from the neutron-activation of the original gold NPs has been 
shown to dissolve negligibly out of the gold NPs cores, in particular after the washing procedure 
during the NP preparation21. Thus, the gold NPs are virtually insoluble21 and therefore, their 
biokinetics is indicated by the 198Au label.  
 
By calculating the 111In to 198Au ratio for each organ and tissue and each time point, major 
differences between the retention of the two radio-isotopes become evident (Figure 2e, f). This 
differential behaviour indicates dissociation and removal of the 111In label from the shell of the 
initial NP. Concerning the stability of the 111In label in respect to its co-localization with the 
polymer shell, we have performed an auxiliary biokinetics studies in C57BL/6 mice. Hereby, a 
soluble form of the 111In radio-isotope (as free ion) and of a complex of 111In with the chelator 
diethylene triamine pentaacetic acid (DTPA) were intravenously injected, in order to distinguish 
the biodistribution of the soluble form (111In ions) versus the chelated form (111In-DTPA) and 
versus the particulate form (polymer coated Au NPs with 111In in the polymer shell, cf. Figure 2c, 
d). By using the same quantitative approach as used for the data in Figure 2, data from Figure 3 
allow for distinguishing whether 111In has been released from the Au cores in the form of free 
ions (i.e. the shell label is lost) or in chelated form (i.e. as fragment from the polymer shell). In 
case of the ionic form 111In is rapidly accumulated (time point 3 h) and retained (time point 24 h) 
in the liver (dark grey bars in Figure 3, Supplementary Fig. 29). However, in the case of the 
chelated form 111In is efficiently excreted by urine (light grey bars in Figure 3).  
 
Most of the 111In as administered in particulate form is retained in the liver (cf. Figure 2c, d). Our 
data do not indicate whether the In in the liver is still attached to the polymer shell and thus the 
Au core, or is present in the form of free ions, as in both cases dominant retention in the liver 
occurs (cf. Figure 2a, b and dark grey bars in Figure 3). On the other hand, the In excreted via 
urine is present in chelated form, as this is the only efficient pathway for renal excretion (cf. the 
light grey bars in Figure 3). Thus, in a likely scenario parts of the polymer shell (with the 
chelated In) come off the Au cores in the liver and these fragments are excreted by urine.  
 
To probe where the polymer shell begins to separate from its Au core in the liver where most NPs 
are found, we performed histology (cf. Figure 2a-d). Au cores with chelated In in their shell 
(without using radioisotopes) were intravenously administered to rats with the same protocols 
used for the biodistribution studies shown in Figure 2. However, no Au NPs were detected in 
tissue slices of the liver when imaged with transmission electron microscopy (TEM) (cf. 
Supplementary Fig. 30 and Supplementary Fig. 31). In order to double-check these findings also 
fluorescence was used for NP detection.  For this purpose we used CdSe/ZnS quantum dots 
(QDs, emission at 605 nm) with the organic fluorophore DY636 (Dyomics, emission at 657 nm) 
in the polymer shell with similar colloidal properties as the Au NPs. The QDs were administered 
to rats with the same protocol, and tissue slices of the liver were imaged with optical microscopy. 
Again, no NP signal (neither from the QD core nor from the fluorophore-labelled shell) could be 
detected above the autofluorescence background level (cf. Supplementary Fig. 33). While the low 
NP doses of 1013 - 1014 NPs per animal thus did not allow for observation of individual NPs in 
the liver slices used for TEM and fluorescence microscopy imaging, inductively coupled plasma 
mass spectrometry (ICP-MS) analyses performed on the entire liver had enough sensitivity for 
detecting the NPs and clearly demonstrated their present in the liver (cf. Supplementary Fig. 32 
and Supplementary Fig. 35), confirming the data with radiolabelled NPs.  
 
Knowing by detection of radiolabels (Figure 2a-d) and ICP-MS that the NPs in fact are 
dominantly retained in the liver, though at concentrations too low to allow for successful 
histology, we attempted to emulate in vivo behaviour of the liver by in vitro investigation on cell 
lines representing different cell types in the liver. We selected Kupffer cells, which are 
specialized stellate macrophages in the liver, and human umbilical vein endothelial cells 
(HUVECs). First, cellular uptake of polymer coated Au NPs and QDs was quantified in terms of 
intracellular Au and Cd/Se, respectively, as quantified by ICP-MS. NPs are incorporate by both 
cell types (Supplementary Fig. 36) and intracellular uptake of Au NPs and QDs is similar (cf. 
Figure 4a, b, and Supplementary Fig. 37). We attribute this to the similar surface chemistry of the 
Au NPs and QDs, though time- and concentration-dependencies differ. Second, the intracellular 
location of the internalized Au NPs and QDs (with a fluorescence label in their polymer shell) 
was determined by confocal microscopy via colocalization with the lysosomal membrane marker 
LAMP-1 (cf. Supplementary Fig. 38). Data demonstrate time- and concentration dependent rise 
of localization of both types of NPs in the lysosomes of both, HUVECs (cf. Figure 4c, d, and 
Supplementary Fig. 39) and Kupffer cells (cf. Supplementary Fig. 40). Thus, our data indicate 
that NPs retained in the liver are localized in the lysosomes of macrophages and of epithelial 
cells. Due to their similar surface chemistry polymer-coated QDs show a similar behaviour as 
polymer-coated Au NPs.  
 
Figure 4e shows that incubating polymer-coated QDs with a DY495 fluorescence label in their 
polymer shell with different proteolytic enzymes (trypsin, pronase, proteinase 3, and cathepsin G) 
leads to the degradation of the polymer shell, as visualized by the removal of the integrated 
fluorescent label from the QDs. Thus, presence of proteolytic enzymes leads to degradation of the 
polymer shell "in test tube". We hypothesized that proteolytic lysosomal enzymes present in 
endosomes and lysosomes may be responsible for the in vitro degradation of the polymer shell. 
HUVECs and Kupffer cells were incubated with polymer-coated QDs. Colocalization analysis of 
the fluorescence originating from the QD core and the fluorescence originating from the 
fluorescence of the DY495 label of the polymer shell indicate that after several hours the polymer 
shell label is partly displaced from the QD label, which is in agreement with findings of others3. 
In the medium the fluorescence of exocytosed QDs has a lower fraction of QD fluorescence 
compared to DY495 fluorescence, as it is found for QDs inside cells that have been analysed after 
cell lysis. Our data also directly show that intracellular enzymatic degradation of internalized 
QDs can cause partial removal of either the DY495-labeled polymer shell or the DY495 label, 
which are subsequently exocytosed as seen in Figure 4f. 
 
The 24 h biodistribution of the polymer-coated 198Au NPs from the present study (Figure 2b) is 
similar to that of 5 nm Au NPs coated with triphenylphosphine sulfonate (TPPS) in previous 
studies22, 23  (Figure 5). Since the protein corona plays a significant role in the determination of 
the biokinetics of the intravenously injected Au NPs, the similar patterns indicate that the protein 
coronas seem to be very similar. For the virtually “naked” TPPS coated Au NPs it was shown 
that the coating was rather quickly removed in a cellular in vitro assay24. This is in agreement 
with our findings in which the polymer coated Au NPs lose parts of their polymer coating in vitro 
as in vivo. Thus, in both cases the protein corona is formed on a partly “naked” surface of the Au 
NPs (i.e. a surface partially stripped off the original organic coating). This is the likely reason that 
leads to a similar biodistribution of TTPS and polymer coated NP.  
 
 
Conclusions 
Using radio-labelled Au cores and polymer shells, we show that the polymer shells of polymer-
coated Au NPs are partially removed in vitro and in vivo. In vivo, NPs are mostly retained in the 
liver and fragments of the organic shell are excreted through the kidneys. In vitro experiments 
show that NPs internalized by HUVEC and Kupffer cells were localized in endosomal and 
lysosomal compartments. A partial separation of the organic shell from the inorganic core is 
caused by proteolytic enzymes present in these compartments. We believe in vivo degradation of 
the polymer shell is due to similar proteolytic digestion. Our findings indicate that the 
physicochemical properties and the integrity of NPs can change dramatically upon internalization 
by cells in vitro and in vivo. This may have potential consequences for drug targeting with NPs 
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Materials and Methods 
 
NP preparation and characterization: Au NPs (core diameter dc = 4.8 ± 0.9 nm, cf. Supplementary 
Fig. 1) were neutron activated, leading to conversion of parts of the Au atoms to the gamma-
emitting isotope 198Au4. The Au cores were coated by an amphiphilic polymer (poly(isobutylene–
alt–maleic anhydride)–graft–dodecyl), to which the indium chelator 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) had been integrated5. After addition of 
111In the resulting double-labelled NPs has a hydrodynamic diameter of dh = 13 ± 1 nm and a 
zeta-potential of -46 ± 16 mV (cf. Supplementary Fig. 14 and Fig. 15). The geometry of the NPs 
is shown in  
Figure 1. For details we refer to a previous publication5. CdSe/ZnS QDs (core diameter of 
dc = 4.7 ± 1 nm, cf. Supplementary Fig. 3) were synthesized according to standard protocol. The 
QDs were coated by the same amphiphilic polymer as the Au NPs, in which organic fluorophores 
were integrated. The QDs had a ζ-potential of -28 ± 4 mV (cf. Supplementary Fig. 20). For 
details we refer to a previous publication5.  
 
Animals: Healthy, female Wistar-Kyoto rats (WKY/Kyo@Rj rats, Janvier, Le Genest Saint Isle, 
France), 8–10 weeks of age (approximately 250 g body weight) were housed in pairs in humidity 
and temperature-controlled ventilated cages on a 12 h day/night cycle. Rodent diet and water 
were provided ad libitum. All experiments were conducted under German federal guidelines for 
the use and care of laboratory animals and were approved by the Regierung von Oberbayern 
(Government of District of Upper Bavaria, Approval No. 55.2-1-54-2531-26-10) and by the 
Institutional Animal Care and Use Committee of the Helmholtz Center Munich. 
 
NP administration and animal maintenance in metabolic cages: The entire administration has 
been already described previously4, 19. Briefly, the rats were anesthetized by inhalation of 5 % 
isoflurane until muscular tonus relaxed. NPs suspensions (50 to 70 µL containing 1-10 µg of 
double-labelled gold NPs) were administered to the animals via intravenous injection into the tail 
vein of the animal. After administration of the NPs suspensions, rats were kept individually in 
metabolic cages for separate collection of total urine and feces. 
 
Sample preparation and radio analysis: One hour or 24 hours post injection, rats were 
anesthetized and euthanized by exsanguination via the abdominal aorta. Radio analysis was 
performed on four rats for each time point according to previously published protocols4, 23. 
Briefly, total organs, tissues, body fluids, the remaining carcass, and total urinary and faecal 
excretions were sampled and analysed γ-spectrometrically4, 19. The 198Au or 111In radioactivities 
of all samples were measured without any further sample preparation by γ-spectroscopy. Small 
organ and tissue samples were analysed in a lead-shielded, 10 mL well type NaI(Tl) scintillation 
detector, while a lead-shielded, 1 L well type NaI(Tl) scintillation detector was used for large 
samples like the remaining carcass. Compton correction was carried out using the gamma 
acquisition analysis software Genie 2000 (Canberra Industries, Rüsselsheim, Germany). Count 
rates were adjusted for physical decay and background radiation. Additionally, the 198Au or 111In 
count rates were calibrated to either a 198Au or 111In reference source at a reference date in order 
to correlate 198Au and 111In radioactivities to the numbers and masses of the Au NPs. Samples 
yielding net counts (i.e. background-corrected counts) in the photo-peak region-of-interest of 
either the 198Au or the 111In γ-spectrum were defined to be below the detection limit when they 
were less than three standard deviations of the background counts of this region-of-interest. 
While dissecting, no organs were cut and all fluids were cannulated when necessary in order to 
avoid cross contamination. We quantitatively determined the entire 198Au and 111In dose 
independently from each other in the entire animal by analysing for each radio-isotope each 
organ and tissue and total excretion. Thus, for each radio-isotope a 100 % balance of the 
biodistribution was performed.  
 Blood correction: Blood contents of organs and the remaining body were calculated according to 
the findings of Oeff et al.20 as described previously22, 23. 
 
Calculations and statistical analysis: All calculated data are given as a percentage of the relevant 
integral radioactivity of all samples in each animal with the standard error of the mean (SEM) for 
both radio-isotopes.  
 
Accompanying “in test tube” and in vitro experiments with QDs: In order to support the in vivo 
observations as obtained with polymer-coated Au NPs with double radionucleotide labelling 
additional "in test tube" and in vitro experiments were performed with polymer-coated QDs with 
double fluorescence labelling (one colour for the inorganic NP core, one colour for the organic 
polymer shell) which had similar geometry, surface chemistry, and colloidal properties. "In test 
tube" polymer coated QDs were incubated with different proteolytic enzymes and resulting 
fragments of the DY495-labelled polymer shell / released DY495 were separated from the NPs 
by filtration. The amount of released fluorescence label from the polymer coating was quantified 
with fluorescence spectroscopy. For in vitro experiments HUVECs and Kupffer cells (which are 
relevant for NPs present in the liver) were exposed to polymer coated QDs-labelled with different 
fluorophore labels in their polymer shell. Colocalization experiments between the QD core and 
the polymer shell label were performed. The fluorescence spectra of exocytosed QDs and QDs 
found in cell lysate were compared (cf. Supplementary Fig. 46 - Supplementary Fig. 49). 
  
Figures 
 
 
 
Figure 1: Sketch of the NPs with double radio-label. Au cores were synthesised in organic phase 
by reduction of Au3+ and the resulting NPs were stabilized by a ligand shell of dodecanethiol. 
Upon neutron activation, some of the Au atoms were converted into the radioactive isotope 198Au, 
which forms the radiolabelled core. A shell of the amphiphilic polymer poly(isobutylene–alt–
maleic anhydride)–graft–dodecyl was then  wrapped around the Au core and rendered the NP 
water-soluble. DOTA was integrated into the polymer shell and was loaded with In (enriched 
with the radioactive isotope 111In, which acted as the shell label). In this way NP core and shell 
are individually labelled by 198Au and 111In, respectively. 
 
 
Figure 2: Biodistribution of double-labelled NPs. Au NPs (with core diameter dc = 4.8 ± 0.9 nm) 
with an 198Au core radiolabel and an 111In shell radiolabel had been intravenously injected into 
the tail vein of Wistar-Kyoto rats and their radioactivities were determined in different organs.  
Graphs show the quantitative balance (i.e. the sum of all 198Au or 111In radioactivities over all 
organs and tissues, the remaining carcass, and total faecal and urinary excretion is 100 %) of the 
1 h and 24 h biodistribution of double-labelled Au NPs. The retentions R, given as mean data 
(± SEM) are denoted in percent of the total radioactivity for the respective radio-isotope (n = 4 
animals per data point). “Remainder” represents radiolabels found in the remaining rest of the 
carcass after sampling of organs, i.e. soft tissues, skin and skeleton, etc. “GIT+feces” represents 
the radiolabels found in the gastro-intestinal-tract and in feces (note that after 1 hour no 
radiolabels were found in feces). “Blood” represents the total content of radiolabels as 
calculated from the measured content in the blood sample and the estimate of the total blood 
volume, cf. Methods. a, b) biodistribution of the 198Au NP core radiolabel. c, d) biodistribution of 
the 111In shell radiolabel. e, f) ratio of 111In shell to 198Au NP radiolabel in each organ and tissue. 
The data show that more 111In shell labels than 198Au core labels were detected in blood, urine, 
and GIT and feces at any time point. Data are also plotted in linear scale in Supplementary Fig. 
25, and enlisted in Supplementary Table 1 and Supplementary Table 2.  
 
Figure 3: Quantitative biodistribution of soluble free 111In ions and 111In-DPTA complexes. 
C57BL/6 mice were intravenously injected with free 111In ions and chelated 111In in the form of 
111In-DPTA complexes. Biodistribution was monitored at 3 h (a) and 24 h (b) by measuring the 
radioactivities of the different organs. The graph shows the percent retention R of 111In for free 
(dark grey bars) and chelated (light grey bars) 111In in whole organs and tissues, the remaining 
carcass without sampled organs, the gastro-intestinal-tract and the total feces “GIT+feces”, and 
urinary excretion. The retentions R are given as mean data (± SEM) and are denoted in percent 
of the total radioactivity for the respective radio-isotope (n = 4 animals per data point). Data 
demonstrate that the biodistribution of 111In ions and of 111In-DPTA chelate complexes is 
different, in particular in liver and urine. 
  
  
Figure 4: Cellular internalization and degradation of polymer coated Au NPs and QDs by 
proteases “in test tube” and in vitro. a, b) ICP-MS analysis of the uptake of (a) Au NPs with In in 
their polymer shell and (b) polymer-coated CdSe/ZnS QDs by HUVECs. Shown is the content (a: 
Au, In; b: Cd) per cell after indicated incubation times with different NP concentrations of cNP = 
1, 5 and 10 nM. c, d) Lysosomal enrichment of (c) fluorescence-labelled Au NPs and (d) CdSe/Zn 
QDs in HUVECs. The fluorescence intensity I(lyso) originating from the NPs is given for 
different NP concentrations cNP. e) Ratio I518/I518(0) of fluorescence intensity of DY495 label 
released from the shell around the QDs after 24 h "in test tube" incubation with phosphate 
buffered saline (PBS, pH = 7.4), in the presence of 10 % fetal bovine serum (serum),  trypsin 
(0.05 %), pronase (0.2 units/mL), proteinase 3 (0.003 units/mL), and cathepsin G (13 units/mL). 
The ratio I518/I518(0) was quantified by measuring the fluorescence I518 of DY495 (@ 518 nm) of 
the released DY495 label after separation from the QD core by ultrafiltration, as compared to 
the original fluorescence I518(0) of the DY495 label attached to the QDs. f) Ratio of QD and 
DY495 fluorescence intensities (I605 /I518) for exocytosed QDs and QDs found inside Kupffer cells 
(cell lysate). Kupffer cells were incubated with the QDs for 22 h followed by additional 3 h 
incubation after removing the free QDs from the medium. All data are given as mean values ± 
standard deviation. Data demonstrate partial removal of the polymer shell from the NP cores in 
vitro. 
  
 
Figure 5: Quantitative 24 h biodistribution of i.v. injected, monodisperse Au NPs (dc = 5 nm) 
coated with triphenylphosphine (TPPS) (dark grey bars; data taken from our previous study 22) 
and of Au NPs (dc = 4.8 ± 0.9 nm) coated with a DOTA-modified polymer shell (light grey bars; 
data taken from Figure 2b) in Wistar-Kyoto rats. For each time point data for the retention R of 
the 198Au cores are given in percent (mean ± SEM; n = 4 animals) of the total radioactivity of 
each entire animal. Data demonstrate that the biodistribution of the Au NPs with the two 
different surface coatings (TPPS versus polymer coating) is similar. 
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